<DOC>
	<DOCNO>NCT02097966</DOCNO>
	<brief_summary>The primary objective program provide Daclatasvir combination Sofosbuvir without Ribavirin subject chronic Hepatitis C high risk liver decompensation death within 12 month leave untreated available therapeutic option .</brief_summary>
	<brief_title>EU : A Multicenter Compassionate Use Program Daclatasvir ( BMS-790052 ) Combination With Sofosbuvir With Without Ribavirin Treatment Subjects With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>This program conduct EU ( Germany , Austria , Norway , The Netherlands , Sweden United Kingdom ) For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Patients chronically infected Hepatitis C Patients high risk liver decompensation death within 12 month leave untreated available therapeutic option Patients &lt; 18 year old Patients contraindication either Daclatasvir ( DCV ) Sofosbuvir ( SOF ) Patients pregnant Creatinine clearance ( CrCl ) â‰¤ 30 mL/min ( estimate Cockcroft Gault formula ) Patients pregnant Women Child Bearing Potential use require contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>